Results 41 to 50 of about 13,979 (215)

Role of anoikis-related gene RAC3 in prognosis, immune microenvironment, and contribution to malignant behavior in vitro and in vivo of bladder urothelial carcinoma

Frontiers in Pharmacology
BackgroundAnoikis disrupts the normal apoptotic process in cells, leading to abnormal proliferation and migration, thereby promoting tumor formation and development.
Yusong Zhou, Shiwei Huang, Bing Yang, Jing Tan, Zhun Zhang, Wei Liu   +5 more
doaj   +1 more source

FAM111B Acts as an Oncogene in Bladder Cancer

, 2023
Bladder cancer (BLCA) is a prevalent malignancy of the urinary system, associated with a high recurrence rate and poor prognosis. FAM111B, which encodes a protein containing a trypsin-like cysteine/serine peptidase domain, has been implicated in the ...
Mingjuan Sun, Jiaping Yang, Lei Peng, Jinqian Li, Sheng Zhang, Ning Huang   +5 more
core   +1 more source

Immunological significance of alternative splicing prognostic signatures for bladder cancer

Heliyon, 2022
Background: Bladder cancer (BLCA) is the most common malignant tumor in the genitourinary system, and the complex tumor microenvironment (TME) of BLCA is the main factor in its difficult treatment. Accumulated evidence supports that alternative splicing (
Xinyun Li, Lin Yang, Wei Huang, Bo Jia, Yu Lai   +4 more
doaj   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Table6_A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.XLSX

, 2023
Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic.
Huihuang Li (1701952), Tiezheng Qi, Yuanqing Dai, Dingshan Deng, Xiaowen Li, Huihuang Li, Xiaowen Li (317720), Neng Liu, Tiezheng Qi (11271606), Yuanqing Dai (15407567), Neng Liu (2118667), Dingshan Deng (8910740)   +11 more
core   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Table_9_Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.xlsx

, 2023
RationaleRNA modifications, containing m6A, m1A, alternative polyadenylation and adenosine-to-inosine RNA editing, involve in critical cancerous immunity and cancerous processes. However, the functional roles of RNA modification writers in bladder cancer
Wen Wen (596162), Yao Zhang, Ying Chen (9697), Wen Wen, Yao Zhang (134381), Ying Chen   +5 more
core   +1 more source

DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT

Advanced Science, EarlyView.
DIXDC1 drives bladder cancer progression by binding and stabilizing DLAT. This axis enhances NEK7 and CCNE2 mRNA stability to promote proliferation and lymphatic metastasis, while limiting copper‐induced DLAT oligomerization to reduce cuproptosis sensitivity, identifying DIXDC1 as a potential target linking metastasis with cuproptosis resistance ...
Hongqiong Li, Liang Cheng, Xiaole Lu, Haonan Dong, Shi Fu, Hongjin Shi, Mingsheng Liu, Chenwei Yang, Yuhang Huang, Zehua Chen, Yawei Zhang, Kaiwen Jie, Xiaoyue Zhang, Xiang Kui, Xinni Ye, Siting Chen, Xu Chen, Haifeng Wang   +17 more
wiley   +1 more source

Image_5_Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.jpeg

, 2023
RationaleRNA modifications, containing m6A, m1A, alternative polyadenylation and adenosine-to-inosine RNA editing, involve in critical cancerous immunity and cancerous processes. However, the functional roles of RNA modification writers in bladder cancer
Wen Wen (596162), Ying Chen (9697), Yao Zhang (134381)   +2 more
core   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

Advanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai, Xin Mei Zhang, Jing Cheng Zhang, Xu Ting Deng, Qiao Liu, Mustafa Hussein Ali, Fang Zhou Yin, Wu Yin   +7 more
wiley   +1 more source